HealthInvest Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

HealthInvest Partners’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$5.67K	Buy	+1,069	New	+$4.89K	0.01%	50

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HealthInvest Partners's PSTX Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022: 1,069 shares worth $5.67K. The stake represents 0.01% of the portfolio and ranks #50 among its holdings.

89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

HealthInvest Partners held 1,069 shares of Poseida Therapeutics, Inc. Common Stock worth $5.67K as of Q4 2022.
Poseida Therapeutics, Inc. Common Stock was a new HealthInvest Partners position in Q4 2022.
Poseida Therapeutics, Inc. Common Stock made up 0.01% of HealthInvest Partners's portfolio in Q4 2022, its #50 holding.
89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.